Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions frequently point out the substantial advantages of using TMB to guide treatment choices for cisplatin-unfit patients, with users expressing enthusiasm and optimism about its potential. For instance, phrases like 'wonderful graph' and references to 'favorable outcomes with first line immunotherapy' illustrate a tone of excitement and validation around the study's findings. This choice of language emphasizes the transformative possibilities of incorporating TMB into clinical practice.
Many discussions indicate a consensus on the importance of tumor mutational burden in treatment decisions, suggesting a partial agreement on its value.
The posts reflect a strong curiosity regarding the implications of TMB for patient outcomes, highlighting its relevance.
Several users engage deeply with the research, referencing specific studies, methodologies, and potential clinical implications.
Participants perceive the research as having a significant influence on treatment strategies for urothelial carcinoma.
Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profile of patients with #urothelial carcinoma recruited in large clinical trials vs real-practice. I'm wondering if we can really extrapolate the data? @OncoAlert https://t.co/EvVkdGR4yA
⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma #bladdercancer https://t.co/CPboYLY08c https://t.co/cQTX0UHL4H
#ICYMI a recent @JCOPO_ASCO podcast w/ @shilpaonc discussed recent #research in tumor mutational burden (TMB) utilizing the @flatironhealth and Foundation Medicine real-world clinico-genomic database. Listen here: https://t.co/eTvBGmpZYm
#NewResearch assessed whether TMB identifies clinical benefit of first-line immunotherapy treatment vs. chemotherapy in metastatic urothelial carcinoma patients. Learn more in @JCOPO_ASCO: https://t.co/RznPlbI6w9 https://t.co/Hq7E50ovlo
@Alfdoc2 @BenWestphalen @ChristianRolfo @pashtoonkasi @NatureMedicine @Nature @OncoAlert @DrawImpacts @GlopesMd @OncBrothers @mtmdphd @VivekSubbiah @mdmanishshah @aparna1024 @marklewismd @isliquidbiopsy @FoundationATCG Still, no question #TMB needs further clinical development. Check out recent papers w @flatironhealth led by @RyonGraf: ▶️TMB in bladder: https://t.co/gPA7W7rbPD ▶️TMB in prostate: https://t.co/dlYP3LLrOW ▶️TMB in gastric: https://t.co/WW7P7dp8Z0 ▶️TMB in NSCLC coming soon!
Dr. Shilpa Gupta discusses how tumor mutational burden (TMB) may identify metastatic urothelial carcinoma (mUC) patients who benefit more from immune checkpoint inhibitors than from carboplatin. This analysis focuses on…
RT @FoundationATCG: #ICYMI a recent @JCOPO_ASCO podcast w/ @shilpaonc discussed recent #research in tumor mutational burden (TMB) utilizing…
#ICYMI a recent @JCOPO_ASCO podcast w/ @shilpaonc discussed recent #research in tumor mutational burden (TMB) utilizing the @flatironhealth and Foundation Medicine real-world clinico-genomic database. Listen here: https://t.co/eTvBGmpZYm
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @geoff_oxnard: @Alfdoc2 @BenWestphalen @ChristianRolfo @pashtoonkasi @NatureMedicine @Nature @OncoAlert @DrawImpacts @GlopesMd @OncBroth…
@Alfdoc2 @BenWestphalen @ChristianRolfo @pashtoonkasi @NatureMedicine @Nature @OncoAlert @DrawImpacts @GlopesMd @OncBrothers @mtmdphd @VivekSubbiah @mdmanishshah @aparna1024 @marklewismd @isliquidbiopsy @FoundationATCG Still, no question #TMB needs further clinical development. Check out recent papers w @flatironhealth led by @RyonGraf: ▶️TMB in bladder: https://t.co/gPA7W7rbPD ▶️TMB in prostate: https://t.co/dlYP3LLrOW ▶️TMB in gastric: https://t.co/WW7P7dp8Z0 ▶️TMB in NSCLC coming soon!
RT @RyonGraf: @MattGalsky At risk of self-promotion, for bladder cancer & IO, consider further validation of TMB: https://t.co/GWp7pvW48Z r…
RT @RyonGraf: @MattGalsky At risk of self-promotion, for bladder cancer & IO, consider further validation of TMB: https://t.co/GWp7pvW48Z r…
RT @RyonGraf: @MattGalsky At risk of self-promotion, for bladder cancer & IO, consider further validation of TMB: https://t.co/GWp7pvW48Z r…
RT @RyonGraf: @MattGalsky At risk of self-promotion, for bladder cancer & IO, consider further validation of TMB: https://t.co/GWp7pvW48Z r…
@MattGalsky At risk of self-promotion, for bladder cancer & IO, consider further validation of TMB: https://t.co/GWp7pvW48Z recent work from collaboration with @shilpaonc
BLADDER: real world data suggest that patients with tumour mutation burden ≥10 have more favourable outcomes with first line immunotherapy (PD-(L)1 inhibition) rather than chemotherapy. https://t.co/xWEdVzNtPg
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus... - https://t.co/3jnKbAMFDW #ScholarAlerts
RT @JCOPO_ASCO: Real-world study by @shilpaonc @RyonGrafIn et al: In pts w #urothelial cancer who are more frail than pts on clinical trial…
RT @JCOPO_ASCO: Real-world study by @shilpaonc @RyonGrafIn et al: In pts w #urothelial cancer who are more frail than pts on clinical trial…
Real-world study by @shilpaonc @RyonGrafIn et al: In pts w #urothelial cancer who are more frail than pts on clinical trials, anti-PD1 axis immunotherapy was more effective than carboplatin in the setting of high #TMB (10 or greater).
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @FoundationATCG: #NewResearch assessed whether TMB identifies clinical benefit of first-line immunotherapy treatment vs. chemotherapy in…
RT @FoundationATCG: #NewResearch assessed whether TMB identifies clinical benefit of first-line immunotherapy treatment vs. chemotherapy in…
RT @FoundationATCG: #NewResearch assessed whether TMB identifies clinical benefit of first-line immunotherapy treatment vs. chemotherapy in…
#NewResearch assessed whether TMB identifies clinical benefit of first-line immunotherapy treatment vs. chemotherapy in metastatic urothelial carcinoma patients. Learn more in @JCOPO_ASCO: https://t.co/RznPlbI6w9 https://t.co/Hq7E50ovlo
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
RT @drenriquegrande: Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profi…
Wonderful graph by @shilpaonc and cols. at https://t.co/mSO8OSSMQh showing crystal clear the differences in the profile of patients with #urothelial carcinoma recruited in large clinical trials vs real-practice. I'm wondering if we can really extrapolate the data? @OncoAlert https://t.co/EvVkdGR4yA
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
Nice work all!! https://t.co/KLPOGjdRDq
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
RT @drenriquegrande: ⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin…
⚡️On @JCOPO_ASCO - Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma #bladdercancer https://t.co/CPboYLY08c https://t.co/cQTX0UHL4H
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
RT @RyonGraf: @VinayMathewTho1 Also just published today... perhaps urothelial carcinoma treatments might become much more precise in comin…
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…
@VinayMathewTho1 Also just published today... perhaps urothelial carcinoma treatments might become much more precise in coming years... HRD and TMB? https://t.co/GWp7pvVwjr
RT @shilpaonc: Just in @JCOPO_ASCO Our work on TMB as a Predictor of First-Line IO vs Carboplatin Benefit in Cisplatin-Unfit pts with mU…